H Lundbeck A/S's experimental Alzheimer's drug fails in late-stage study

H Lundbeck A/S's experimental Alzheimer's drug fails in late-stage study

Danish drugmaker H Lundbeck A/S announced Thursday that its experimental Alzheimer's drug has failed to show desired results in a late-stage study. The company shared that both doses of the drug called idalopirdine have shown low efficacy rate and did not lessen cognitive decline rate on a scale known as the ADAS-cog.

The drug developed along with Japan's Otsuka Pharmaceutical Co Ltd is being tested on patients suffering from mild to moderate Alzheimer's disease. The failure of Danish company’s experimental drug shows how difficult it has become for drugmakers to come up with an effective medicine for this devastating disease.

It has become all the more important to come up medication as global cases of dementia are expected to increase by three times by 2050. But Lundbeck has not lost hope on its drug and cleared that the two other late stage clinical trials would continue to take place as per the plans. Their results are expected in the first quarter of 2017.

Dr. Anders Gersel Pedersen, Chief Scientific Officer at Lundbeck, mentioned, “We are disappointed about the outcome of this study. The phase II data were very encouraging but unfortunately, these data failed to replicate those findings”.

Lundbeck had to lower its dosage level in the mid-stage study owing to liver toxicity, shared analysts. RBC Capital Markets analysts doubt that low-dose idalopirdine would be able to show the desired results in the remaining trials as well.

Many experts think that just one drug would not be able to combat Alzheimer's progress. As per them, combinations of medicines would be required to stop the disease. Eli Lilly and Co's experimental drug solanezumab’s late stage results are also expected to be publicized in the fourth quarter.